{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:21:11Z","timestamp":1767986471036,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.urology.2006.09.019","type":"journal-article","created":{"date-parts":[[2007,2,2]],"date-time":"2007-02-02T17:24:27Z","timestamp":1170437067000},"page":"78-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Long-Term Follow-up of Patients with Stage T1 High-Grade Transitional Cell Carcinoma Managed by Bacille Calmette-Gu\u00e9rin Immunotherapy"],"prefix":"10.1016","volume":"69","author":[{"given":"David","family":"Margel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raanan","family":"Tal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shai","family":"Golan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani","family":"Kedar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dov","family":"Engelstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Baniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2006.09.019_bib1","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0022-5347(05)65969-1","article-title":"Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy","volume":"166","author":"Dutta","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.09.019_bib2","first-page":"254","article-title":"The T1 bladder tumor","volume":"8","author":"Herr","year":"1990","journal-title":"Semin Urol"},{"key":"10.1016\/j.urology.2006.09.019_bib3","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0022-5347(17)51695-X","article-title":"Superficial bladder cancer: progression and recurrence","volume":"130","author":"Heney","year":"1983","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.09.019_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0022-5347(17)43864-X","article-title":"Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor?","volume":"137","author":"Jakse","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.09.019_bib5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000472824","article-title":"Radical cystectomy\u2014often too late?","volume":"13","author":"Stockle","year":"1987","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2006.09.019_bib6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Gu\u00e9rin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.09.019_bib7","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0022-5347(17)37241-5","article-title":"Bacillus Calmette-Gu\u00e9rin therapy for high risk stage T1 superficial bladder cancer","volume":"147","author":"Eure","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.09.019_bib8","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-5347(17)36724-1","article-title":"Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Gu\u00e9rin therapy","volume":"148","author":"Cookson","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.09.019_bib9","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/S0022-5347(01)66692-8","article-title":"Bacillus Calmette-Gu\u00e9rin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results","volume":"154","author":"Pansadoro","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.09.019_bib10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.clon.2005.07.005","article-title":"A second look at the pT1 G3 bladder tumour","volume":"17","author":"Harland","year":"2005","journal-title":"Clin Oncol"},{"key":"10.1016\/j.urology.2006.09.019_bib11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0090-4295(98)00369-0","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin treatment for stage T1 grade 3 transitional cell carcinoma of the bladder","volume":"52","author":"Baniel","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.urology.2006.09.019_bib12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0090-4295(01)01324-3","article-title":"Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years","volume":"58","author":"Patard","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.urology.2006.09.019_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0090-4295(01)01603-X","article-title":"Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Gu\u00e9rin: 18-year experience","volume":"59","author":"Pansadoro","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.urology.2006.09.019_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000019664","article-title":"Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success","volume":"34","author":"Lebret","year":"1998","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2006.09.019_bib15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0090-4295(99)00116-8","article-title":"Intravesical bacille Calmette-Gu\u00e9rin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up","volume":"54","author":"Hurle","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.urology.2006.09.019_bib16","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1097\/01.ju.0000066840.42991.4a","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients","volume":"169","author":"Peyromaure","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.09.019_bib17","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1046\/j.1464-410X.1997.00431.x","article-title":"Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome","volume":"80","author":"Herr","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.urology.2006.09.019_bib18","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S0022-5347(05)67523-4","article-title":"Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Gu\u00e9rin","volume":"163","author":"Brake","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.09.019_bib19","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.09.019_bib20","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0022-5347(17)38439-2","article-title":"Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Gu\u00e9rin versus intravesical bacillus Calmette-Gu\u00e9rin in superficial bladder cancer","volume":"145","author":"Lamm","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.09.019_bib21","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.09.019_bib22","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0022-5347(05)66333-1","article-title":"Control group and maintenance treatment with bacillus Calmette-Gu\u00e9rin for carcinoma in situ and\/or high grade bladder tumors","volume":"165","author":"Palou","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.09.019_bib23","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.09.019_bib24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ucl.2005.02.002","article-title":"Optimal management of the T1G3 bladder cancer","volume":"32","author":"Manoharan","year":"2005","journal-title":"Urol Clin North Am"},{"issue":"2","key":"10.1016\/j.urology.2006.09.019_bib25","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/sj.bjc.6602684","article-title":"p53 Immunodetection of liquid-based processed urinary samples helps to identify bladder tumours with a higher risk of progression","volume":"93","author":"Piaton","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urology.2006.09.019_bib26","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/sj.bjc.6602732","article-title":"Prognostic impact of FAS\/CD95\/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression","volume":"93","author":"Yamana","year":"2005","journal-title":"Br J Cancer"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429506021418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429506021418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:46:21Z","timestamp":1758764781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429506021418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0090429506021418"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2006.09.019","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Follow-up of Patients with Stage T1 High-Grade Transitional Cell Carcinoma Managed by Bacille Calmette-Gu\u00e9rin Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2006.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}